Clinical Insights Into Novel Immune Checkpoint Inhibitors
The success of immune checkpoint inhibitors (ICIs), notably anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1), and programmed death ligand-1 (PD-L1), has revolutionized treatment options for solid tumors. However, the lack of respons...
Main Authors: | Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.681320/full |
Similar Items
-
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
by: Shuang Qin, et al.
Published: (2019-11-01) -
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators.
by: Isabelle eLe Mercier, et al.
Published: (2015-08-01) -
Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection
by: Danielle M. Clements, et al.
Published: (2021-03-01) -
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer
by: Sara SF Al‐Badran, et al.
Published: (2021-03-01) -
Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function
by: Clara Degos, et al.
Published: (2019-04-01)